Publications by authors named "Michael A Becker"

Claim this Profile
C
Circularly Polarized Luminescence Without External Magnetic Fields from Individual CsPbBr Perovskite Quantum Dots.
Virginia Oddi, Chenglian Zhu, Michael A Becker, Yesim Sahin, Dmitry N Dirin

ACS Nano· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of the Relationship Between Serum Urate Levels, Clinical Manifestations of Gout, and Death From Cardiovascular Causes in Patients Receiving Febuxostat or Allopurinol in an Outcomes Trial.
Kenneth G Saag, Michael A Becker, William B White, Andrew Whelton, Jeffrey S Borer

Arthritis Rheumatol· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Robust Tipless Positioning Device for Near-Field Investigations: Press and Roll Scan (PROscan).
Hsuan-Wei Liu, Michael A Becker, Korenobu Matsuzaki, Randhir Kumar, Stephan Götzinger

ACS Nano· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Unraveling the Origin of the Long Fluorescence Decay Component of Cesium Lead Halide Perovskite Nanocrystals.
Michael A Becker, Caterina Bernasconi, Maryna I Bodnarchuk, Gabriele Rainò, Maksym V Kovalenko

ACS Nano· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trion Emission Dominates the Low-Temperature Photoluminescence of CdSe Nanoplatelets.
Felipe V Antolinez, Freddy T Rabouw, Aurelio A Rossinelli, Robert C Keitel, Ario Cocina, Michael A Becker

Nano Lett· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Polymer and Colloid Highlights.
Gabriele Rainò, Michael A Becker, Maryna I Bodnarchuk, Rainer F Mahrt, Thilo Stöferle

Chimia (Aarau)· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Febuxostat Extended and Immediate Release in Patients With Gout and Renal Impairment: A Phase III Placebo-Controlled Study.
Kenneth G Saag, Michael A Becker, Andrew Whelton, Barbara Hunt, Majin Castillo

Arthritis Rheumatol· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long Exciton Dephasing Time and Coherent Phonon Coupling in CsPbBrCl Perovskite Nanocrystals.
Michael A Becker, Lorenzo Scarpelli, Georgian Nedelcu, Gabriele Rainò, Francesco Masia

Nano Lett· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Superfluorescence from lead halide perovskite quantum dot superlattices.
Gabriele Rainò, Michael A Becker, Maryna I Bodnarchuk, Rainer F Mahrt, Maksym V Kovalenko

Nature· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of febuxostat extended release and immediate release in patients with gout and moderate renal impairment: phase II placebo-controlled study.
Lhanoo Gunawardhana, Michael A Becker, Andrew Whelton, Barbara Hunt, Majin Castillo

Arthritis Res Ther· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout.
William B White, Kenneth G Saag, Michael A Becker, Jeffrey S Borer, Philip B Gorelick

N Engl J Med· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bright triplet excitons in caesium lead halide perovskites.
Michael A Becker, Roman Vaxenburg, Georgian Nedelcu, Peter C Sercel, Andrew Shabaev

Nature· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lesinurad Combined With Allopurinol: A Randomized, Double-Blind, Placebo-Controlled Study in Gout Patients With an Inadequate Response to Standard-of-Care Allopurinol (a US-Based Study).
Kenneth G Saag, David Fitz-Patrick, Jeff Kopicko, Maple Fung, Nihar Bhakta, Michael A Becker

Arthritis Rheumatol· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Summary of the 2015 Purine and Pyrimidine Society/Purine Metabolic Patients Association H. Anne Simmonds Memorial Lecture.
Michael A Becker

Nucleosides Nucleotides Nucleic Acids· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Febuxostat on Renal Function in Gout Patients With Moderate-to-Severe Renal Impairment.
Kenneth G Saag, Andrew Whelton, Michael A Becker, Patricia MacDonald, Barbara Hunt

Arthritis Rheumatol· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An open-label, 6-month study of allopurinol safety in gout: The LASSO study.
Michael A Becker, David Fitz-Patrick, Hyon K Choi, Nicola Dalbeth, Chris Storgard

Semin Arthritis Rheum· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Infusion-related reactions with pegloticase, a recombinant uricase for the treatment of chronic gout refractory to conventional therapy.
Herbert S B Baraf, Robert A Yood, Faith D Ottery, John S Sundy, Michael A Becker

J Clin Rheumatol· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Urate transporters: transforming the face of hyperuricemia and gout.
Michael A Becker, Peter A Simkin, Leif B Sorensen

J Rheumatol· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term management of gout: nonpharmacologic and pharmacologic therapies.
Yashaar Chaichian, Saima Chohan, Michael A Becker

Rheum Dis Clin North Am· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout.
Peter E Lipsky, Leonard H Calabrese, Arthur Kavanaugh, John S Sundy, David Wright, Michael A Becker

Arthritis Res Ther· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A revised estimate of the burden of illness of gout.
Albert Wertheimer, Robert Morlock, Michael A Becker

Curr Ther Res Clin Exp· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term safety of pegloticase in chronic gout refractory to conventional treatment.
Michael A Becker, Herbert S B Baraf, Robert A Yood, Aileen Dillon, Janitzia Vázquez-Mellado

Ann Rheum Dis· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tophus burden reduction with pegloticase: results from phase 3 randomized trials and open-label extension in patients with chronic gout refractory to conventional therapy.
Herbert S B Baraf, Michael A Becker, Sergio R Gutierrez-Urena, Edward L Treadwell, Janitzia Vazquez-Mellado

Arthritis Res Ther· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol.
Saima Chohan, Michael A Becker, Patricia A MacDonald, Solomon Chefo, Robert L Jackson

Arthritis Care Res (Hoboken)· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treating hyperuricemia of gout: safety and efficacy of febuxostat and allopurinol in older versus younger subjects.
Michael A Becker, Patricia A MacDonald, Barbara Hunt, Lhanoo Gunawardhana

Nucleosides Nucleotides Nucleic Acids· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis